PCSK9 Inhibitor causes a decrease in the level of oxidatively modified low-density lipoproteins in patients with coronary artery diseases
- 作者: Lankin V1, Tikhaze A1, Viigimaa M2, Chazova I1
-
隶属关系:
- FSBI "National Medical Research Cardiology Center" of the Ministry of Health of the Russian Federation
- Center for Cardiology of Tallinn University of Technology
- 期: 卷 90, 编号 9 (2018)
- 页面: 27-30
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/32985
- DOI: https://doi.org/10.26442/terarkh201890927-30
- ID: 32985
如何引用文章
全文:
详细
作者简介
V Lankin
FSBI "National Medical Research Cardiology Center" of the Ministry of Health of the Russian Federation
Email: lankin941@mail.ru
д.б.н., проф., руководитель отд. биохимии свободнорадикальных процессов Moscow, Russia
A Tikhaze
FSBI "National Medical Research Cardiology Center" of the Ministry of Health of the Russian Federation
Email: allatikhaze@yandex.ru
д.м.н., проф., в.н.с. отд. биохимии свободнорадикальных процессов Moscow, Russia
M Viigimaa
Center for Cardiology of Tallinn University of Technology
Email: MargusViigimaa@regionaalhaigla.ee
д.м.н., проф., руководитель центра кардиологии Tallinn, Estonia
I Chazova
FSBI "National Medical Research Cardiology Center" of the Ministry of Health of the Russian Federation
Email: c34h@yandex.ru
д.м.н., проф., акад. РАН, директор Института клинической кардиологии им. А.Л. Мясникова Moscow, Russia
参考
- Nawarskas J.J. HMG-CoA reductase inhibitors and coenzyme Q10. Cardiol Rev. 2005;13(2):76-9. https://doi.org/10.1097/01.crd. 0000154790. 42283.a1
- Lankin V.Z, Tikhaze A.K, Kukharchuk V.V, Konovalova G.G, Pisarenko O.I, Kaminnyi A.I, Shumaev K.B, Belenkov Y.N. Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins. Mol Cell Biochem. 2003;249(1-2):129-40.
- Lankin V.Z, Tikhaze A.K. Free radical lipoperoxidation during atherosclerosis and antioxidative therapy of this disease. In: Tomasi A., et al., eds. Free Radicals, Nitric Oxide and Inflammation: Molecular, Biochemical and Clinical Aspects. Amsterdam, etc.: IOS Press, NATO Science Series. 2003;344:218-31.
- Moosmann B, Behl C. Selenoprotein synthesis and side - effects of statins. Lancet. 2004;363(9412):892-4. https://doi.org/10.1016/S0140-6736(04)15739-5
- Littlefield N, Beckstrand R.L, Luthy K.E. Statins' effect on plasma levels of Coenzyme Q10 and improvement in myopathy with supplementation. J Am Assoc Nurse Pract. 2014;26(2):85-90. https://doi.10.1002/2327-6924.12046
- Pisarenko O.I, Studneva I.M, Lankin V.Z, Konovalova G.G, Tikhaze A.K, Kaminnaya V.I, Belenkov Y.N. Inhibitor of beta - hydroxyl - beta - methylglutaryl coenzyme A reductase decreases energy supply to the myocardium in rats. Bull Exp Biol Med. 2001;132(4):956-8.
- Steinberg D, Witztum J.L. Oxidized low - density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol. 2010;30(12):2311-6. https://doi.org/10.1161/ATVBAHA.108.179697
- Lankin V.Z, Tikhaze A.K. Role of Oxidative Stress in the Genesis of Atherosclerosis and Diabetes Mellitus: A Personal Look Back on 50 Years of Research. Сurr Аging Sci. 2017;10(1):18-25. https://doi.org/10.2174/ 1874609809666160926142640
- Lankin V.Z, Tikhaze A.K, Konovalova G.G, Kumskova E.M, Shumaev K.B. Aldehyde - dependent modification of low density lipoproteins. In: Handbook of Lipoprotein Research. NY. Nova Sci. 2010:85-107.
- Pedersen T.R. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering. Am J Cardiovasc Drugs. 2010;10 (Suppl 1):10-7. https://doi.org/10.2165/1158822-S0-000000000-00000
- Koren M.J, Lundqvist P, Bolognese M, Neutel J.M, Monsalvo M.L, Yang J, Kim J.B, Scott R, Wasserman S.M, Bays H. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23): 2531-40. https://doi.org/10.1016/j.jacc.2014.03.018
- Koren M.J, Sabatine M.S, Giugliano R.P, Langslet G, Wiviott S.D, Kassahun H, Ruzza A, Ma Y, Somaratne R, Raal F.J. Long - term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years from the Open-Label OSLER-1 Extension Study. JAMA Сardiol. 2017;2(6):598-607. https://doi.org/10.1001/jamacardio.2017. 0747
- Viigimaa M, Abina J, Zemtsovskaya G, Tikhaze A, Konovalova G, Kumskova E, Lankin V. Malondialdehyde - modified low - density lipoproteins as biomarker for atherosclerosis. Blood Press. 2010;19(3):164-8. https://doi.org/10.3109/08037051.2010.484158
- Lankin V.Z, Konovalova G.G, Tikhaze A.K, Shumaev K.B, Belova-Kumskova E.M, Grechnikova M.A, Viigimaa M. Aldehyde inhibition of antioxidant enzymes in blood of diabetic patients. J Diabetes. 2016;8(3):398-404. https://doi.org/10.1111/1753-0407.12309
- Chrysant S.G. New onset diabetes mellitus induced by statins: current evidence. Postgrad Med. 2017;129(4):430-5. https://doi.org/10.1080/ 00325481.2017.1292107